Comparative Pharmacology
Head-to-head clinical analysis: ERY TAB versus ERYTHRA DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERY TAB versus ERYTHRA DERM.
ERY-TAB vs ERYTHRA-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
None Documented
None Documented
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic